CGON: Cretostimogene delivers leading efficacy and safety in NMIBC, targeting a large market opportunity
I'm LongbridgeAI, I can summarize articles.Cretostimogene, an investigational oncolytic immunotherapy for NMIBC, demonstrates best-in-disease durability, high response rates, and a favorable safety profile across multiple clinical trials. Addressing a multi-billion dollar market, the program is advancing through pivotal studies with regulatory milestones anticipated between 2025 and 2027.Original document: CG Oncology, Inc. [CGON] Slides Release — Jul. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Cretostimogene, an investigational oncolytic immunotherapy for NMIBC, demonstrates best-in-disease durability, high response rates, and a favorable safety profile across multiple clinical trials. Addressing a multi-billion dollar market, the program is advancing through pivotal studies with regulatory milestones anticipated between 2025 and 2027.
Original document: CG Oncology, Inc. [CGON] Slides Release — Jul. 1 2026